These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A method for the detection and confirmation of antibodies to hepatitis C virus in dried blood spots.
    Author: Parker SP, Cubitt WD, Ades AE.
    Journal: J Virol Methods; 1997 Nov; 68(2):199-205. PubMed ID: 9389410.
    Abstract:
    This study describes the development and evaluation of a cost effective test rationale for the detection of anti-HCV in dried blood spots. Samples were screened using an 'in house' IgG ELISA that incorporated the recombinant proteins c22-3, c200 and NS5. Confirmation of specific antibody to HCV was by a modification of the immunoblot RIBA 3.0. An extensive panel of well evaluated anti-HCV positive and negative samples from the UK and South Africa were used to assess the sensitivity and specificity of the two tests. One third of the anti-HCV positive samples had been typed. All anti-HCV positive samples were detected by the 'in house' screening EIA. Test/negative optical density ratios showed that more than 95% of reactive samples produced values greater than 5.0. Antibodies to HCV could be detected in a wide range of samples derived from asymptomatic and symptomatic patients and of different genotypes, with similar sensitivity. The presence of anti-HCV could be confirmed by RIBA 3.0 in samples with low reactivity but not in anti-HCV negative samples. Furthermore the immunoblot assay successfully increased specificity by screening out false reactive EIA samples that might occur in an epidemiological survey of a multi-ethnic population. While hepatitis C virus (HCV) is a major etiological agent of post-transfusion and community acquired non-A, non-B hepatitis, little is known about the epidemiology of HCV in the UK. A cost-effective method using dried blood spots to determine anti-HCV IgG in subjects which could be used in large-scale epidemiological studies is described. Samples were screened using an in-house IgG ELISA incorporating the recombinant proteins c22-3, c200, and NS5, while specific antibody to HCV was confirmed using a modified immunoblot RIBA 3.0. A panel of well evaluated anti-HCV positive and negative samples from the UK and South Africa were used to assess the sensitivity and specificity of the 2 tests. All anti-HCV positive samples were detected by the in-house screening EIA. Test/negative optical density ratios showed that more than 95% of reactive samples produced values greater than 5.0. Antibodies to HCV could be detected in a wide range of samples derived from asymptomatic and symptomatic patients and of different genotypes, with similar sensitivity. The presence of anti-HCV could be confirmed by RIBA 3.0 in samples with low reactivity, but not in anti-HCV negative samples. The immunoblot assay increased specificity by screening out false reactive EIA samples.
    [Abstract] [Full Text] [Related] [New Search]